IVRO's Q3 Packed with Positives; Sales, Profits, and U.S. Government/Global Support for Animal Welfare
InVitro International (OTCQB: IVRO) reported strong financial results for Q3 FY '25, with sales reaching $234,430, marking a 39.7% increase from Q3 FY '24. Year-to-date sales hit $675,080, up 14.4% year-over-year, while net income reached $95,556 for the first three quarters, showing a 17.1% improvement.
CEO W. Richard Ulmer highlighted increasing interest from chemical companies due to cost and time advantages of in vitro testing over animal testing. The company's growth is further supported by Canada's ban on new cosmetics involving animal testing and U.S. government agencies' acceptance of validated in vitro test results.
InVitro International (OTCQB: IVRO) ha riportato risultati finanziari solidi per il terzo trimestre dell'anno fiscale 2025, con vendite che hanno raggiunto 234.430 $, segnando un aumento del 39,7% rispetto al terzo trimestre dell'anno fiscale 2024. Le vendite da inizio anno hanno toccato 675.080 $, in crescita del 14,4% rispetto all'anno precedente, mentre l'utile netto per i primi tre trimestri 猫 stato di 95.556 $, con un miglioramento del 17,1%.
Il CEO W. Richard Ulmer ha sottolineato il crescente interesse da parte delle aziende chimiche grazie ai vantaggi in termini di costi e tempi dei test in vitro rispetto ai test sugli animali. La crescita dell'azienda 猫 inoltre sostenuta dal divieto canadese sui nuovi cosmetici che prevedono test su animali e dall'accettazione da parte delle agenzie governative statunitensi dei risultati validati dei test in vitro.
InVitro International (OTCQB: IVRO) report贸 s贸lidos resultados financieros para el tercer trimestre del a帽o fiscal 2025, con ventas que alcanzaron $234,430, lo que representa un incremento del 39.7% respecto al tercer trimestre del a帽o fiscal 2024. Las ventas acumuladas en el a帽o llegaron a $675,080, un aumento del 14.4% interanual, mientras que el ingreso neto para los primeros tres trimestres fue de $95,556, mostrando una mejora del 17.1%.
El CEO W. Richard Ulmer destac贸 el creciente inter茅s de las compa帽铆as qu铆micas debido a las ventajas en costos y tiempo de las pruebas in vitro frente a las pruebas en animales. El crecimiento de la empresa tambi茅n est谩 respaldado por la prohibici贸n en Canad谩 de nuevos cosm茅ticos que involucren pruebas en animales y la aceptaci贸n por parte de agencias gubernamentales de EE.UU. de resultados validados de pruebas in vitro.
InVitro International (OTCQB: IVRO)鞚� 2025 須岅硠鞐半弰 3攵勱赴 臧曤牓頃� 鞛 鞁れ爜鞚� 氤搓碃頄堨溂氅�, 毵れ稖鞚� 234,430雼煬搿� 2024 須岅硠鞐半弰 3攵勱赴 雽�牍� 39.7% 歃濌皜頄堨姷雼堧嫟. 鞐瓣皠 雸勳爜 毵れ稖鞚� 675,080雼煬搿� 鞝勲厔 雽�牍� 14.4% 靸侅姽頄堨溂氅�, 靾滌澊鞚奠潃 觳橃潓 靹� 攵勱赴 霃欖晥 95,556雼煬搿� 17.1% 臧滌劆霅橃棃鞀惦媹雼�.
CEO W. Richard Ulmer電� 鞚胳泊鞕�(in vitro) 韰岇姢韸戈皜 霃欕 鞁ろ棙鞐� 牍勴暣 牍勳毄瓿� 鞁滉皠 氅挫棎靹� 鞚挫爯鞚� 鞛堨柎 頇旐暀 須岇偓霌れ潣 甏�鞁澊 歃濌皜頃橁碃 鞛堧嫟瓿� 臧曥“頄堨姷雼堧嫟. 霕愴暅 旌愲倶雼れ潣 鞁犼窚 頇旍灔頀� 霃欕 鞁ろ棙 旮堨鞕� 氙戈淡 鞝曤秬 旮瓣磤霌れ澊 瓴�歃濍悳 鞚胳泊鞕� 韰岇姢韸� 瓴瓣臣毳� 鞚胳爼頃橂姅 鞝愳澊 須岇偓鞚� 靹膘灔鞚� 霋冯皼旃晿瓿� 鞛堨姷雼堧嫟.
InVitro International (OTCQB : IVRO) a annonc茅 de solides r茅sultats financiers pour le troisi猫me trimestre de l'exercice 2025, avec des ventes atteignant 234 430 $, soit une augmentation de 39,7 % par rapport au troisi猫me trimestre de l'exercice 2024. Les ventes cumul茅es depuis le d茅but de l'ann茅e ont atteint 675 080 $, en hausse de 14,4 % sur un an, tandis que le b茅n茅fice net pour les trois premiers trimestres s'茅l猫ve 脿 95 556 $, soit une am茅lioration de 17,1 %.
Le PDG W. Richard Ulmer a soulign茅 l'int茅r锚t croissant des entreprises chimiques en raison des avantages en termes de co没ts et de temps des tests in vitro par rapport aux tests sur animaux. La croissance de la soci茅t茅 est 茅galement soutenue par l'interdiction au Canada des nouveaux cosm茅tiques impliquant des tests sur animaux et par l'acceptation par les agences gouvernementales am茅ricaines des r茅sultats valid茅s des tests in vitro.
InVitro International (OTCQB: IVRO) meldete starke Finanzergebnisse f眉r das dritte Quartal des Gesch盲ftsjahres 2025, mit einem Umsatz von 234.430 $, was einer Steigerung von 39,7 % gegen眉ber dem dritten Quartal des Gesch盲ftsjahres 2024 entspricht. Der Umsatz seit Jahresbeginn erreichte 675.080 $, ein Anstieg von 14,4 % im Jahresvergleich, w盲hrend der Nettogewinn f眉r die ersten drei Quartale bei 95.556 $ lag und eine Verbesserung von 17,1 % zeigte.
CEO W. Richard Ulmer hob das wachsende Interesse von Chemieunternehmen hervor, das auf den Kosten- und Zeitvorteilen von In-vitro-Tests gegen眉ber Tierversuchen beruht. Das Wachstum des Unternehmens wird zus盲tzlich durch das Kanadas Verbot neuer Kosmetika mit Tierversuchen und die Anerkennung validierter In-vitro-Testergebnisse durch US-Regierungsbeh枚rden unterst眉tzt.
- Q3 sales increased by 39.7% year-over-year to $234,430
- YTD sales up 14.4% to $675,080
- Net income grew 17.1% for the first three quarters
- Canada banned new cosmetics involving animal testing
- U.S. government agencies now accept validated in vitro test results
- Increasing inquiries from chemical companies
- None.
Placentia, California--(Newsfile Corp. - August 5, 2025) - Today, InVitro International (OTCQB: IVRO) reported FY '25, Q3 sales of
CEO and Chairman, W. Richard Ulmer, expressed delight with IVRO's noteworthy progress: "In recent months we received quite a few new inquiries. Many are from chemical companies who are realizing that animal testing is much more expensive, takes much longer to do, and now often is not required. Canada just prohibited the introduction of new cosmetics if animal testing is part of their creation; and several U.S. government agencies announced they will accept validated in vitro test results, which IVRO offers. We expect our government to pass similar legislation as virtually all other civilized countries have in the past decade. We remain excited and committed to our mission."
About InVitro International, Inc.
InVitro International, Inc., headquartered in Placentia, California, was founded in 1985 and is a customer and technology driven provider of non-animal testing methods. The Company's testing technologies are designed to produce Regulatory Agencies' approved data regarding corrosivity and ocular/dermal irritation, which correlate with animal and human test results. IVRO's technology is commercialized globally through test kits and partner laboratory services.
This release may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. These risks and uncertainties include but are not limited to acceptance of the Company's technology by customers or regulatory agencies, changes in market conditions and other competitive factors. The forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update such statements.
Company Contact:
W. Richard Ulmer
Chief Executive Officer and Chairman
(800)246-8487
[email protected]
To view the source version of this press release, please visit
FAQ
What were IVRO's Q3 2025 financial results?
How is IVRO benefiting from changing regulations in animal testing?
Why are chemical companies showing increased interest in IVRO's services?
What regulatory changes are supporting IVRO's business growth?
